  | GUREGHIAN, V., HERBST, H., KOZAR, I., MIHAJLOVIC, K., Malod-Dognin, N., Ceddia, G., ANGELI, C., WURTH-MARGUE, C., RANDIC, T., PHILIPPIDOU, D., TETSI NOMIGNI, M., HEMEDAN, A., TRANCHEVENT, L.-C., LONGWORTH, J., Bauer, M., BADKAS, A., GAIGNEAUX, A., Muller, A., OSTASZEWSKI, M., ... KREIS, S. (October 2023). A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma. Cancer Gene Therapy, 30 (10), 1330 - 1345. doi:10.1038/s41417-023-00640-z  Peer Reviewed verified by ORBi |
 | Bintener, T., Pires Pacheco, M. I., Philippidou, D., Margue, C., Kishk, A., Del Mistro, G., Di Leo, L., Moscardo Garcia, M., Halder, R., Sinkkonen, L., De Zio, D., Kreis, S., Kulms, D., & Sauter, T. (26 July 2023). Metabolic modelling-based in silico drug target prediction identifies six novel repurposable drugs for melanoma. Cell Death and Disease, 14 (468). doi:10.1038/s41419-023-05955-1 Peer reviewed |
 | RANDIC, T., MAGNI, S., PHILIPPIDOU, D., Margue, C., GRZYB, K., PREIS, J. R., WROBLEWSKA, J. P., NAZAROV, P., MITTELBRONN, M., FRAUENKNECHT, K., SKUPIN, A., & KREIS, S. (25 July 2023). Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response. Cell Reports, 42 (7), 112696. doi:10.1016/j.celrep.2023.112696 Peer Reviewed verified by ORBi |
 | Kozar, I., Philippidou, D., Margue, C., Gay, L., Renne, R., & Kreis, S. (2021). Cross-Linking Ligation and Sequencing of Hybrids (qCLASH) Reveals an Unpredicted miRNA Targetome in Melanoma Cells. Cancers. doi:10.3390/cancers13051096 Peer Reviewed verified by ORBi |
 | Kirchmeyer, M., Servais, F., Ginolhac, A., Nazarov, P. V., Margue, C., Philippidou, D., Nicot, N., Behrmann, I., Haan, C., & Kreis, S. (2020). Systematic transcriptional profiling of responses to STAT1- and STAT3- activating cytokines in different cancer types. Journal of Molecular Biology. doi:10.1016/j.jmb.2020.09.011 Peer Reviewed verified by ORBi |
 | Walbrecq, G., Lecha, O., Gaigneaux, A., Fougeras, M. R., Philippidou, D., Margue, C., Tetsi Nomigni, M., Bernardin, F., Dittmar, G., Behrmann, I., & Kreis, S. (2020). Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles. Cancers. doi:10.3390/cancers12030692 Peer Reviewed verified by ORBi |
 | Margue, C., Philippidou, D., Kozar, I., Cesi, G., Felten, P., Kulms, D., Letellier, E., Haan, C., & Kreis, S. (February 2019). Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Journal of Experimental and Clinical Cancer Research, 38 (1). doi:10.1186/s13046-019-1038-x Peer Reviewed verified by ORBi |
 | Cesi, G., Philippidou, D., Kozar, I., Kim, Y. J., Bernardin, F., Van Niel, G., Wienecke-Baldacchino, A., Felten, P., Letellier, E., Dengler, S., Nashan, D., Haan, C., & Kreis, S. (2018). A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Molecular Cancer, (17:145). doi:10.1186/s12943-018-0886-x Peer Reviewed verified by ORBi |
 | Kreis, S., Kozar, I., Cesi, G., Margue, C., & Philippidou, D. (2017). Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochimica et Biophysica Acta. doi:10.1016/j.bbagen.2017.04.005 Peer reviewed |
 | Margue, C., Reinsbach, S., Philippidou, D., Beaume, N., Walters, C., Schneider, J., Nashan, D., Behrmann, I., & Kreis, S. (2015). Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget, 6 (14), 12110-27. doi:10.18632/oncotarget.3661 Peer Reviewed verified by ORBi |
 | Margue, C., Philippidou, D., Reinsbach, S., Schmitt, M., Behrmann, I., & Kreis, S. (05 September 2013). New Target Genes of MITF-Induced microRNA-211 Contribute to Melanoma Cell Invasion. PLoS ONE, 8 (9). doi:10.1371/journal.pone.0073473 Peer Reviewed verified by ORBi |
 | Nazarov, P. V. A., Reinsbach, S., Muller, A. A., Nicot, N. A., Philippidou, D., Vallar, L. A., & Kreis, S. (2013). Interplay of microRNAs, transcription factors and target genes: Linking dynamic expression changes to function. Nucleic Acids Research, 41 (5), 2817-2831. doi:10.1093/nar/gks1471 Peer Reviewed verified by ORBi |
  | Reinsbach, S., Nazarov, P. V., Philippidou, D., Schmitt, M., Wienecke, A., Muller, A., Vallar, L., Behrmann, I., & Kreis, S. (2012). Dynamic regulation of microRNA expression following interferonγ- induced gene transcription. RNA Biology, 9 (7), 987-989. doi:10.4161/rna.20494 Peer Reviewed verified by ORBi |
 | Schmitt, M. J., Philippidou, D., Reinsbach, S., Margue, C., Wienecke-Baldacchino, A., Nashan, D., Behrmann, I., & Kreis, S. (2012). Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Communication and Signaling, 10. doi:10.1186/1478-811X-10-41 Peer Reviewed verified by ORBi |
 | Philippidou, D., Schmitt, M., Moser, D., Margue, C., Nazarov, P. V., Muller, A., Vallar, L., Nashan, D., Behrmann, I., & Kreis, S. (2010). Signatures of MicroRNAs and selected MicroRNA target genes in human melanoma. Cancer Research, 70 (10), 4163-4173. doi:10.1158/0008-5472.CAN-09-4512 Peer Reviewed verified by ORBi |
 | Kreis, S., Philippidou, D., Margue, C., & Behrmann, I. (10 May 2008). IL-24: a classic cytokine and/or a potential cure for cancer? Journal of Cellular and Molecular Medicine, 12 (6A), 2505-2510. doi:10.1111/j.1582-4934.2008.00372.x Peer reviewed |
 | Kreis, S., Philippidou, D., Margue, C., Rolvering, C., Haan, C., Dumoutier, L., Renauld, J.-C., & Behrmann, I. (2007). Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, 2 (12), 1300. doi:10.1371/journal.pone.0001300 Peer Reviewed verified by ORBi |